Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons

Simple item page
dc.contributor.authorEdward E. Walsh
dc.contributor.authorDaniel Eiras
dc.contributor.authorJohn Woodside
dc.contributor.authorQin Jiang
dc.contributor.authorMichael A. Patton
dc.contributor.authorGonzalo Pérez Marc
dc.contributor.authorConrado J. Llapur
dc.contributor.authorMika Rämet
dc.contributor.authorYasushi Fukushima
dc.contributor.authorNazreen Hussen
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T13:58:13Z
dc.date.available2026-03-22T13:58:13Z
dc.date.issued2025
dc.descriptionCitaciones: 34
dc.description.abstractHigh RSV neutralizing titers were observed 1 month after RSVpreF vaccination in persons aged ≥60 years, with similarly robust responses across subgroups. These immune responses corresponded with high RSVpreF VE against RSV-associated LRTI. RSVpreF had a favorable safety profile over 2 seasons. Clinical Trials Registration. NCT05035212; EudraCT, 2021-003693-31.
dc.identifier.doi10.1093/cid/ciaf061
dc.identifier.urihttps://doi.org/10.1093/cid/ciaf061
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/43784
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofClinical Infectious Diseases
dc.sourceUniversity of Rochester Medical Center
dc.subjectMedicine
dc.subjectImmunogenicity
dc.subjectTiter
dc.subjectVaccination
dc.subjectPlacebo
dc.subjectImmunology
dc.subjectVirology
dc.subjectAntigen
dc.titleEfficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons
dc.typearticle

Files

Collections

Artículo Científico Publicado